BRPI0819212A2 - Métodos de tratamento de inflamação neurogênica crônica usando toxinas modificadas de clostrídio - Google Patents

Métodos de tratamento de inflamação neurogênica crônica usando toxinas modificadas de clostrídio

Info

Publication number
BRPI0819212A2
BRPI0819212A2 BRPI0819212-0A BRPI0819212A BRPI0819212A2 BR PI0819212 A2 BRPI0819212 A2 BR PI0819212A2 BR PI0819212 A BRPI0819212 A BR PI0819212A BR PI0819212 A2 BRPI0819212 A2 BR PI0819212A2
Authority
BR
Brazil
Prior art keywords
treatment
methods
neurogenic inflammation
chronic neurogenic
modified clostridium
Prior art date
Application number
BRPI0819212-0A
Other languages
English (en)
Inventor
Kei Roger Aoki
Joseph Francis
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0819212A2 publication Critical patent/BRPI0819212A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0819212-0A 2007-10-23 2008-10-21 Métodos de tratamento de inflamação neurogênica crônica usando toxinas modificadas de clostrídio BRPI0819212A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US98202107P 2007-10-23 2007-10-23
US7622808P 2008-06-27 2008-06-27
US9069208P 2008-09-10 2008-09-10
PCT/US2008/080570 WO2009055350A1 (en) 2007-10-23 2008-10-21 Methods of treating chronic neurogenic inflammation using modified clostridial toxins

Publications (1)

Publication Number Publication Date
BRPI0819212A2 true BRPI0819212A2 (pt) 2015-06-16

Family

ID=40218954

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819212-0A BRPI0819212A2 (pt) 2007-10-23 2008-10-21 Métodos de tratamento de inflamação neurogênica crônica usando toxinas modificadas de clostrídio

Country Status (11)

Country Link
US (1) US20090104234A1 (pt)
EP (1) EP2214696A1 (pt)
JP (1) JP2011514307A (pt)
KR (1) KR20100088683A (pt)
CN (1) CN101903035A (pt)
AU (1) AU2008316988A1 (pt)
BR (1) BRPI0819212A2 (pt)
CA (1) CA2703364A1 (pt)
IL (1) IL205280A0 (pt)
MX (1) MX2010004488A (pt)
WO (1) WO2009055350A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20100303794A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
US20100303757A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
US20100303791A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US20100303789A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases
US20100303798A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Neurotrophin Retargeted Endopepidases
US20100303756A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Interleukin Retargeted Endopepidases
US8198229B2 (en) * 2009-05-29 2012-06-12 Allergan, Inc. Methods of treating urogenital-neurological disorders using galanin retargeted endopepidases
ES2912569T3 (es) 2009-08-28 2022-05-26 Teva Pharmaceuticals Int Gmbh Métodos para tratar el dolor visceral administrando anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de la calcitonina
US20120207734A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases
US20120207743A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
CN111454931A (zh) 2012-11-21 2020-07-28 益普生生物创新有限公司 用于制备经蛋白水解处理的多肽的方法
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
HK1248737A1 (zh) 2015-03-26 2018-10-19 哈佛大学校长及研究员协会 工程改造的肉毒杆菌神经毒素
CN108137654A (zh) * 2015-05-15 2018-06-08 内布拉斯加大学董事会 适用于将分子递送进入选定细胞的工程改造的肉毒梭菌毒素
EP3504226A1 (en) * 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
AU2017331593B2 (en) 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
US20210290740A1 (en) * 2018-07-23 2021-09-23 Universitetssykehuset Nord-Norge Hf Neurotoxin b for use in the treatment of skin diseases
KR102174197B1 (ko) * 2019-06-12 2020-11-04 주식회사 앤씨비아이티 생산성이 향상된 비독성 프로테아제

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2006A (en) * 1841-03-16 Clamp for crimping leather
US4189426A (en) * 1976-04-12 1980-02-19 Hoffmann-La Roche, Inc. Recombinant hormonal compositions and method
US4481139A (en) * 1983-04-13 1984-11-06 Board Of Regents, The University Of Texas System Peptide antagonists of substance P
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
JPS60248659A (ja) * 1984-05-25 1985-12-09 Microbial Chem Res Found ３−〔ｎ−（メルカプトアシル）〕アミノ−４−アリ−ル酪酸誘導体及びそれを有効成分とする鎮痛剤
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5410019A (en) * 1987-09-24 1995-04-25 The Administrators Of The Tulane-Educational Fund Therapeutic peptides
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
ATE138102T1 (de) * 1991-02-19 1996-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von cysteinfreien peptiden
EP0823486A3 (en) * 1991-06-27 2004-02-11 Genelabs Technologies, Inc. Method for inhibiting the binding of a dna-binding protein to duplex dna
US5891842A (en) * 1993-04-09 1999-04-06 Trustees Of Tufts College Methodology for eliciting an analgesic response in a living subject
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
JP3122319B2 (ja) * 1994-05-02 2001-01-09 アソシエーティド ユニバーシティーズ，インコーポレイティド 錫−１１７ｍ−含有放射性治療剤
EP1086702B1 (en) * 1994-05-09 2005-04-13 BINDER, William J. Presynaptic neurotoxins for treatment of migraine headache
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5846216A (en) * 1995-04-06 1998-12-08 G & P Technologies, Inc. Mucous membrane infusor and method of use for dispensing medications
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9818548D0 (en) * 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
DE60032367T3 (de) * 1999-08-25 2011-03-10 Allergan, Inc., Irvine Aktivierbare rekombinante neurotoxine
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6500436B2 (en) * 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6641820B1 (en) * 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
CA2595115C (en) * 2004-12-01 2014-01-21 Health Protection Agency Fusion proteins for treating, preventing or ameliorating pain
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain

Also Published As

Publication number Publication date
KR20100088683A (ko) 2010-08-10
AU2008316988A1 (en) 2009-04-30
CN101903035A (zh) 2010-12-01
US20090104234A1 (en) 2009-04-23
IL205280A0 (en) 2010-12-30
WO2009055350A1 (en) 2009-04-30
CA2703364A1 (en) 2009-04-30
JP2011514307A (ja) 2011-05-06
EP2214696A1 (en) 2010-08-11
MX2010004488A (es) 2010-06-17

Similar Documents

Publication Publication Date Title
IL205280A0 (en) Methods of treating chronic neurogenic inflammation using modified clostridial toxins
IL281675A (en) Injectable botulinum toxin formulations
BRPI0817775A2 (pt) Métodos de tratar distúrbios urogenitais-neurológicos usando toxinas clostridiais modificadas
BRPI0910259A2 (pt) métodos de tratamento de inflamação
EP2167528A4 (en) MODIFIED TOXINS
PT3111954T (pt) Métodos de tratamento da espondilite anquilosante usando anticorpos anti-il-17
BR112012001325A2 (pt) tratamento de distúrbios do fígado com inibidaores de pi3k
EP2419128A4 (en) REMOVED BOTULINUM NEUROTOXIN
BRPI0917130A2 (pt) biomarcadores para tratamento anti-tnf de colite ulcerativa e transtornos relacionados
PL2190883T3 (pl) Sposób obróbki biomasy
EP2424873A4 (en) NOVEL GALECTIN GALACTOSIDHEMMER
BRPI0910854A2 (pt) métodos de tratamento
DK2069798T3 (da) Elisa til vegf
DK2293816T3 (da) Fremgangsmåder til behandling af reumatoid arthritis
DK2337837T3 (da) Alpha-amylase-blandinger og fremgangsmåder til anvendelse heraf
DK3276004T3 (da) Fremgangsmåder til behandling af kronisk nyresygdom
EP2268297A4 (en) MODIFIED TOXINS
EP2385831A4 (en) SMALL MOLECULAR HEMMER OF NADS, NAMNAT AND NMNAT
BR112012004246A2 (pt) métodos para tratar inflamação neurogênica crônica usando uma toxina clostridial modificada
BRPI0923635A2 (pt) pesquisa audiovisual e interface de navegação
EP2291957A4 (en) MEDIA PROCESSING POWER
EP2404592A4 (en) HAIR TREATMENT COMPOSITION
DE112009003766T8 (de) Sputter-Vorrichtung und Sputter-Verfahren
BRPI1010516A2 (pt) Métodos de tratamento de edema relacionados à isquemia-reperfusão
EP2146744A4 (en) THERAPEUTIC BETA-GLUCAN COMPOSITIONS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.